Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits
Abstract Background In this study, seven adjuvants were compared for use with Plasmodium falciparum DiCo-Apical Membrane Antigen 1 (Pf-DiCo-AMA1), with the aim to identify an ideal adjuvant which yields high antibody titres and potentially broadens the responses in clinical trials. The following adj...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | BMC Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12865-019-0307-y |
id |
doaj-33f9092cc20c49399d671936c02d01cc |
---|---|
record_format |
Article |
spelling |
doaj-33f9092cc20c49399d671936c02d01cc2020-11-25T03:51:57ZengBMCBMC Immunology1471-21722019-07-0120111210.1186/s12865-019-0307-yIdentification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbitsSumera Younis0Bart W. Faber1Clemens H.M. Kocken2Edmond J. Remarque3Biomedical Primate Research Centre, Department of ParasitologyBiomedical Primate Research Centre, Department of ParasitologyBiomedical Primate Research Centre, Department of ParasitologyBiomedical Primate Research Centre, Department of ParasitologyAbstract Background In this study, seven adjuvants were compared for use with Plasmodium falciparum DiCo-Apical Membrane Antigen 1 (Pf-DiCo-AMA1), with the aim to identify an ideal adjuvant which yields high antibody titres and potentially broadens the responses in clinical trials. The following adjuvant formulations were evaluated: SE, SE-GLA, Liposomes, Liposomes-GLA, CoVaccine HT™, ImSaVac-P and ImSaVac-P o/w. The study was performed in rabbits, which were immunized with FVO-AMA1 in combination with one of the seven adjuvants. Antibody levels (humoral responses) and functional activity of the antibodies induced against malaria vaccine candidate AMA1 were evaluated. Thus, in this study the ideal adjuvant is expected to induce high functional antibody levels, a long-lived response, and a broad cross-strain activity. Results AMA1 formulated in all adjuvants was immunogenic. However, the magnitude of the immune responses differed between the seven adjuvants. The highest IgG levels were observed for the CoVaccine HT™ group, this was statistically significant for all four AMA1 variants versus all other adjuvant groups. No differences were observed in the breadth of the humoral response, i.e., increased recognition of AMA1 variants. Also, Growth Inhibition Activity (GIA) for both Plasmodium falciparum strains (FCR3 – homologous to FVO AMA1 protein and NF54 – heterologous to FVO AMA1 protein) were significantly higher in the CoVaccine HT™ group as compared to the other adjuvant groups. Conclusions In brief, all seven vaccine – adjuvant formulations were immunogenic. The magnitude of the immune responses differed between the seven adjuvants. No statistically significant differences were observed in the breadth of the humoral response, nor in longevity of the response. Nevertheless, AMA1 formulated in CoVaccine HT™ appeared as the best adjuvant for use in clinical trials.http://link.springer.com/article/10.1186/s12865-019-0307-yAMA1Plasmodium falciparumAdjuvantsSESE-GLALiposomes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sumera Younis Bart W. Faber Clemens H.M. Kocken Edmond J. Remarque |
spellingShingle |
Sumera Younis Bart W. Faber Clemens H.M. Kocken Edmond J. Remarque Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits BMC Immunology AMA1 Plasmodium falciparum Adjuvants SE SE-GLA Liposomes |
author_facet |
Sumera Younis Bart W. Faber Clemens H.M. Kocken Edmond J. Remarque |
author_sort |
Sumera Younis |
title |
Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits |
title_short |
Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits |
title_full |
Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits |
title_fullStr |
Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits |
title_full_unstemmed |
Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits |
title_sort |
identification of adjuvants for clinical trials performed with plasmodium falciparum ama1 in rabbits |
publisher |
BMC |
series |
BMC Immunology |
issn |
1471-2172 |
publishDate |
2019-07-01 |
description |
Abstract Background In this study, seven adjuvants were compared for use with Plasmodium falciparum DiCo-Apical Membrane Antigen 1 (Pf-DiCo-AMA1), with the aim to identify an ideal adjuvant which yields high antibody titres and potentially broadens the responses in clinical trials. The following adjuvant formulations were evaluated: SE, SE-GLA, Liposomes, Liposomes-GLA, CoVaccine HT™, ImSaVac-P and ImSaVac-P o/w. The study was performed in rabbits, which were immunized with FVO-AMA1 in combination with one of the seven adjuvants. Antibody levels (humoral responses) and functional activity of the antibodies induced against malaria vaccine candidate AMA1 were evaluated. Thus, in this study the ideal adjuvant is expected to induce high functional antibody levels, a long-lived response, and a broad cross-strain activity. Results AMA1 formulated in all adjuvants was immunogenic. However, the magnitude of the immune responses differed between the seven adjuvants. The highest IgG levels were observed for the CoVaccine HT™ group, this was statistically significant for all four AMA1 variants versus all other adjuvant groups. No differences were observed in the breadth of the humoral response, i.e., increased recognition of AMA1 variants. Also, Growth Inhibition Activity (GIA) for both Plasmodium falciparum strains (FCR3 – homologous to FVO AMA1 protein and NF54 – heterologous to FVO AMA1 protein) were significantly higher in the CoVaccine HT™ group as compared to the other adjuvant groups. Conclusions In brief, all seven vaccine – adjuvant formulations were immunogenic. The magnitude of the immune responses differed between the seven adjuvants. No statistically significant differences were observed in the breadth of the humoral response, nor in longevity of the response. Nevertheless, AMA1 formulated in CoVaccine HT™ appeared as the best adjuvant for use in clinical trials. |
topic |
AMA1 Plasmodium falciparum Adjuvants SE SE-GLA Liposomes |
url |
http://link.springer.com/article/10.1186/s12865-019-0307-y |
work_keys_str_mv |
AT sumerayounis identificationofadjuvantsforclinicaltrialsperformedwithplasmodiumfalciparumama1inrabbits AT bartwfaber identificationofadjuvantsforclinicaltrialsperformedwithplasmodiumfalciparumama1inrabbits AT clemenshmkocken identificationofadjuvantsforclinicaltrialsperformedwithplasmodiumfalciparumama1inrabbits AT edmondjremarque identificationofadjuvantsforclinicaltrialsperformedwithplasmodiumfalciparumama1inrabbits |
_version_ |
1724485301789786112 |